LDLR and infection: LDLs were confirmed to negatively compete with HCV entry and infection; furthermore, competition experiments using either recombinant soluble peptides corresponding to the LDL-R ectodomain or monoclonal antibodies against similar domain revealed a dose-dependent inhibition of HCV entry into PHH.